This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.
Herceptin (Trastuzumab) injection was the first HER2-targeted therapy for breast cancer. It is a monoclonal antibody that binds to HER2 receptors present on the surface of HER2-positive tumor cells, blocking them from receiving growth signals and flagging them for destruction by the immune system.
Herceptin IV, either alone or in combination with targeted therapies/chemotherapies is indicated for the treatment of patients with HER2-positive early breast cancer (EBC), metastatic breast cancer (MBC), and metastatic gastric cancer or cancer of the gastro-esophageal junction.
If a patient becomes pregnant while receiving Herceptin, or within 7 months following the last dose of Herceptin, please immediately report pregnancy to the local Roche Adverse Event Line at
In case of any adverse events or safety queries, please contact:
If you have a scientific query related to one of Roche's products, please contact:
M-PK-00001707
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country.Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.
Please be aware that you are leaving this website.